This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Rutgers, The State University of New Jersey, Merck + Co., Inc.. Active years: 2014-2021.
Company Filing History:
3 out of 1,492 
2 out of 4,770 
Years Active: 2014-2021
Title: The Innovations of Stephen A. Parent
Introduction
Stephen A. Parent is an accomplished inventor based in Belle Mead, NJ (US). He has made significant contributions to the field of medical diagnostics, particularly in the area of fungal resistance testing. With a total of 3 patents, his work has had a notable impact on the development of assays for detecting drug resistance.
Latest Patents
Among his latest patents, Stephen A. Parent has developed assays for resistance to echinocandin-class drugs. These nucleic acid amplification assays target mutations in two short sections of the fungal gene FKS1. Research has shown that mutations in these target sequences correlate with resistance to echinocandin-class drugs. The assays may include detection methods such as sequencing or labeled hybridization probes. Additionally, he has created primers, probes, and reagent kits for performing these assays.
Career Highlights
Stephen A. Parent has worked with prestigious institutions, including Rutgers, The State University of New Jersey, and Merck & Co., Inc. His experience in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Some of his notable coworkers include David S. Perlin and Cameron M. Douglas. Their collaboration has likely enriched the research environment and fostered innovative solutions in their field.
Conclusion
Stephen A. Parent's work exemplifies the importance of innovation in medical diagnostics. His patents and collaborations have paved the way for advancements in understanding drug resistance, ultimately benefiting patient care and treatment options.